TICKERNERD
Menu
BOLDBOLDHealthcare · Biotechnology

BOLD Stock Forecast: Boundless Bio, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.84
0.00% on the day

The 1 Wall Street analysts covering Boundless Bio, Inc. hold a median 12-month price target of $4 — +40.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 11 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$64.6M
Ticker Nerd rank
84 / 100
Median analyst target
$4.00
Analysts covering
1
Revenue$0.0
Operating income−$24.4M
Net income−$23.7M
Free cash flow−$21.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.0%
1M
+3.3%
YTD
+136.7%
1Y
+144.8%
From 52W high
−5.3%
From 52W low
+170.5%
$1.05
$3.00
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BOLD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Boundless Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
95
Issuance
94
Size
80
Accruals
78
Growth
71
Revisions
54
Quality
45
Volatility
39
Value
20

Momentum (95): The shares have been drifting up relative to others.

Value (20): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BOLD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BOLD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26BOLDHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +40.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
11 Aug 2025HC Wainwright & Co.MaintainsBuy$5.00 → $4.00
2 June 2025HC Wainwright & Co.InitiatesBuy—
28 May 2025Leerink PartnersDowngradeMarket Perform—
13 Dec 2024GuggenheimDowngradeNeutral—
22 Apr 2024GuggenheimInitiatesBuy—
22 Apr 2024Leerink PartnersInitiatesOutperform—
22 Apr 2024Piper SandlerInitiatesOverweight—
9 Dec 2019Evercore ISI GroupDowngradeIn-Line—
6 Dec 2019JP MorganDowngradeNeutral—
4 Dec 2019Chardan CapitalDowngradeNeutral$60
4 Dec 2019SVB LeerinkDowngradeMarket Perform—
3 Dec 2019BairdUpgradeNeutral—
3 Dec 2019BMO CapitalDowngradeMarket Perform$47 → $60
3 Dec 2019CitigroupUpgradeNeutral$30 → $60
3 Dec 2019GuggenheimDowngradeNeutral—
3 Dec 2019HC Wainwright & Co.DowngradeNeutral$60
3 Dec 2019Piper JaffrayDowngradeNeutral—
3 Dec 2019Piper SandlerDowngradeNeutral$55 → $60
3 Dec 2019Raymond JamesDowngradeMarket Perform—
3 Dec 2019WedbushDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BOLD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BOLD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Boundless Bio, Inc. returned +144.8% against +17.5% for the S&P 500, dividends included.

BOLD vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26BOLDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BOLD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Boundless Bio, Inc. (BOLD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 72% of US stocks

Price / sales
—
Price / book
1.0×

Cheaper than 74% of US stocks

EV / EBITDA
0.1×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−67.9%

Higher than 18% of US stocks

Return on assets
−32.8%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Boundless Bio, Inc. (BOLD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Boundless Bio, Inc. has a market value of $64.6M and an enterprise value of −$8.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$64.0M.

  • Diluted earnings per share, trailing twelve months: $−2.86.

  • Free cash flow in the twelve months to 30 June 2026: −$56.7M.

  • Shares outstanding: 22.5M.

  • Trailing P/E: 0.2×; forward P/E: −2.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Boundless Bio, Inc. employs 28 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

BOLD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BOLDBoundless Bio, Inc.$64.6M
84
ELOXEloxx Pharmaceuticals, Inc.$63.6M
13
SPROSpero Therapeutics, Inc.$63.7M
83
LONALeonaBio, Inc.$64.4M
40
DWTXDogwood Therapeutics, Inc.$65.9M
37
HYFTMindWalk Holdings Corp.$60.9M
58
XBITXBiotech, Inc.$66.8M
31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Boundless Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BOLD news & analysis

Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer

GlobeNewsWire · 9 Sept 2026neutral

Callio Therapeutics, a clinical-stage biotech developing dual-payload antibody-drug conjugates for cancer, announced the appointment of Zachary Hornby as Chief Executive Officer. Co-founder Piers Ingram transitions to Senior Advisor while remaining on the board, and founding CSO Jerome Boyd-Kirkup moves to Senior Scientific Advisor.

Why it matters — A BOLD watcher would care because this leadership change at a fellow ADC-focused oncology company signals broader executive movement within the cancer-therapeutics space that BOLD operates in.

FAQ

Frequently asked questions about BOLD stock

What is the BOLD stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Boundless Bio, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BOLD stock a buy right now?

Of the 1 analysts covering Boundless Bio, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Boundless Bio, Inc. 84 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BOLD?

As at 11 Sept 2026, Boundless Bio, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will BOLD stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +40.8% from the last close, and Ticker Nerd's factor model ranks Boundless Bio, Inc. 84 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BOLD stock forecast for 2030?

No analyst covering Boundless Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BOLD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has BOLD stock performed over the past year?

Boundless Bio, Inc. returned +144.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Boundless Bio, Inc. do?

Boundless Bio Inc. is a clinical-stage oncology company focused on developing precision cancer therapies for tumors driven by oncogene amplification.

What is the latest news on BOLD?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer". Callio Therapeutics, a clinical-stage biotech developing dual-payload antibody-drug conjugates for cancer, announced the appointment of Zachary Hornby as Chief Executive Officer. Co-founder Piers Ingram transitions to Senior Advisor while remaining on the board, and founding CSO Jerome Boyd-Kirkup moves to Senior Scientific Advisor.

Company

About Boundless Bio, Inc.

Boundless Bio Inc. is a clinical-stage oncology company focused on developing precision cancer therapies for tumors driven by oncogene amplification. Its work centers on extrachromosomal DNA (ecDNA), a biological mechanism that can fuel cancer growth, adaptation, and resistance to existing treatments. Using its proprietary Spyglass platform, Boundless Bio identifies ecDNA-related targets and designs ecDNA-directed therapeutic candidates intended to disrupt the pathways cancer cells use to survive. The company’s current pipeline includes oral small-molecule programs such as BBI-940 and other ecDNA-directed therapies being evaluated in clinical studies across hard-to-treat cancer types. Boundless Bio Inc. operates in the biotechnology sector and serves the broader oncology market with a research-driven approach aimed at addressing unmet needs in patients with oncogene-amplified cancers.

CEO Mr. Zachary D. Hornby · 28 employees · United States · https://boundlessbio.com